Literature DB >> 1165136

The acute effect of 2-bromo-a-ergocryptine (CB-154) on anterior pituitary hormones and free fatty acids in man.

G Tolis, E J Pinter, H G Friesen.   

Abstract

CB-154 was administered to six healthy subjects in three different single doses - 1 mg, 2,5 mg, and 3 mg. Growth hormone, prolactin, follicle stimulating hormone, luteinizing hormone, cortisol, blood sugar and free fatty acids were determined. 2.5 and 3 mg doses of CB-154 induced a significant rise in growth hormone and free fatty acids, while prolactin decreased. In addition, CB-154 prevented the circadian fall of plasma cortisol. There were no changes in follicle stimulating hormone, luteinizing hormone or blood sugar levels.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1165136

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  5 in total

1.  Growth hormone and prolactin response to bromocriptine in patients with Huntington's chorea.

Authors:  R J Chalmers; R H Johnson; H J Keogh; R N Nanda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-02       Impact factor: 10.154

Review 2.  Pharmacology of bromocriptine in health and disease.

Authors:  A E Mehta; G Tolis
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

3.  Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormone.

Authors:  E del Pozo; K Schlüter; E Nüesch; J Rosenthaler; L Kerp
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Effect of bromocriptine on maturity onset diabetes.

Authors:  A H Barnett; C Chapman; K Gailer; C J Hayter
Journal:  Postgrad Med J       Date:  1980-01       Impact factor: 2.401

Review 5.  The endocrine profile of bromocriptine: its application in endocrine diseases.

Authors:  I Lancranjan
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.